ZURICH (Reuters) – Novartis has received approval from the U.S. Food and Drug Administration for its Beovu drug to treat a cause of vision loss, the Swiss pharmaceuticals company said on Tuesday.
Beovu injections are used to treat wet age-related macular degeneration, a condition which can eventually lead to blindness and affects around 20 million people worldwide, the company said.
Reporting by John Revill; Editing by Michelle Martin
Our Standards:The Thomson Reuters Trust Principles.
Source news reuters.com, click here to read the full news.
